Is Eli Lilly on a Fruitless Quest?
Alzheimer's disease is a space that has seen a lot of failure from pharmaceutical companies, including Eli Lilly , whose drug solanezumab has failed two phase 3 trials. But now, the company is going back and giving it one more shot. In this video, Motley Fool health care analyst David Williamson tells us why, in this particular space, achieving any results at all may be a huge financial win, and whether Eli Lilly should in fact be pushing for this drug in a limited capacity or if it's chasing a rabbit down a hole that may ultimately elude it.
Over the next two years, Eli Lilly will see nearly $0.40 of every $1.00 in sales exposed to generic competition. How does the company plan to respond to this huge patent cliff? Better yet, what does this mean for investors? In a brand new premium report on Eli Lilly, The Motley Fool's top pharmaceuticals analyst delves into everything investors need to know about the stock today. Simply click here now to claim your copy.
The article Is Eli Lilly on a Fruitless Quest? originally appeared on Fool.com.
Brenton Flynn has no positions in the stocks mentioned above. David Williamson owns shares of Pfizer. Follow him on Twitter @MotleyDavid. The Motley Fool owns shares of Johnson & Johnson. Motley Fool newsletter services recommend Elan and Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.